RESUMEN
PURPOSE: Infusate osmolarity, pH, and cytotoxicity were investigated as risk factors for midline catheter failure. METHODS: An experimental, randomized, controlled, blinded trial was conducted using an ovine model. Two 10-cm, 18-gauge single-lumen midline catheters were inserted into the cephalic veins of sheep. The animals were divided into 6 study arms and were administered solutions of vancomycin 4 mg/mL (a low-cytotoxicity infusate) or 10 mg/mL (a high-cytotoxicity infusate), doxycycline 1 mg/mL (an acidic infusate), or acyclovir 3.5 mg/mL (an alkaline infusate) and 0.9% sodium chloride injection; or 1 of 2 premixed Clinimix (amino acids in dextrose; Baxter International) products with respective osmolarities of 675 mOsm/L (a low-osmolarity infusate) and 930 mOsm/L (a mid-osmolarity infusate). Contralateral legs were infused with 0.9% sodium chloride injection for control purposes. Catheter failure was evaluated by assessment of adverse clinical symptoms (swelling, pain, leakage, and occlusion). A quantitative vessel injury score (VIS) was calculated by grading 4 histopathological features: inflammation, mural thrombus, necrosis, and perivascular reaction. RESULTS: Among 20 sheep included in the study, the overall catheter failure rate was 95% for test catheters (median time to failure, 7.5 days; range, 3-14 days), while 60% of the control catheters failed before or concurrently (median time to failure, 7 days; range, 4.5-14 days). Four of the 6 study arms (all but the Clinimix 675-mOsm/L and acyclovir 3.5-mg/mL arms) demonstrated an increase in mean VIS of ≥77% in test vs control legs (P ≤ 0.034). Both pain and swelling occurred at higher rates in test vs control legs: 65% vs 10% and 70% vs 50%, respectively. The mean difference in rates of occlusive pericatheter mural thrombus between the test and control arms was statistically significant for the vancomycin 10-mg/mL (P = 0.0476), Clinimix 930-mOsm/L (P = 0.0406), and doxycycline 1-mg/mL (P = 0.032) arms. CONCLUSION: Administration of infusates of varied pH, osmolarity, and cytotoxicity via midline catheter resulted in severe vascular injury and premature catheter failure; therefore, the tested infusates should not be infused via midline catheters.
Asunto(s)
Catéteres de Permanencia , Falla de Equipo , Concentración Osmolar , Animales , Femenino , Masculino , Aminoácidos/administración & dosificación , Aminoácidos/química , Antiinfecciosos/administración & dosificación , Antiinfecciosos/química , Concentración de Iones de Hidrógeno , Dolor/etiología , Factores de Riesgo , Ovinos , Cloruro de Sodio/administración & dosificación , Cloruro de Sodio/química , Factores de TiempoRESUMEN
PURPOSE: The purpose of this report is to share our experience with optimizing home parenteral nutrition (HPN) and hydration therapy for an HPN consumer who desired to run a marathon. METHODS: A 34-year-old woman with idiopathic gastroparesis necessitating HPN and intravenous (IV) hydration desired to train for a marathon. For short runs, prerun and/or postrun hydration were adequate, but a marathon (26.2 miles) would be too long to run without IV hydration. During training, we instructed our consumer to record weights (pre/post run), ambient temperature, running distance, and duration of time. These data were used to calculate her sweat rate and estimate hydration volume during the marathon. RESULTS: Ambient temperature was a significant factor influencing sweat rate. The estimate temperature for the marathon was 65 °F; therefore, our consumer would have an estimated sweat rate of approximately 720 mL/h. This exceeded the amount of fluid that could be infused during the marathon; therefore, we advised our consumer to overhydrate prior to the race. Initial postrace urine output was low and concentrated but returned to baseline after postrace hydration. Our consumer did not experience any symptoms of dehydration and had only minor muscle soreness. CONCLUSIONS: Our consumer was able to complete a marathon with IV hydration. We have shown that with careful preparation, calculation, and planning, our HPN consumer was able to adequately maintain her state of hydration and accomplish her goal of running a marathon.
Asunto(s)
Deshidratación/prevención & control , Gastroparesia/dietoterapia , Nutrición Parenteral en el Domicilio , Resistencia Física , Carrera , Administración Intravenosa , Adulto , Atletas , Femenino , Humanos , Calidad de Vida , Temperatura , Desequilibrio Hidroelectrolítico/prevención & controlRESUMEN
This research workshop in 2009 grew out of a concern in the United States, Europe, and other countries with advanced medicine that it was time to revisit the parenteral requirements for a number of micronutrients. Critical questions sought to be answered included the following: Were there micronutrients not routinely added that should be part of a parenteral nutrition (PN) formula? Were other micronutrients present but in inappropriate amounts? How are various micronutrient requirements altered in the critically or chronically ill?